Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry.
JSON
Blilie A, Mulliqi N, Ji X, Szolnoky K, Boman SE, Titus M, Gonzalez GM, Asenjo J, Gambacorta M, Libretti P, Gudlaugsson E, Kjosavik SR, Egevad L, Janssen EAM, Eklund M, Kartasalo K
Commun Med (Lond) 5 (1) 425 [2025-10-15; online 2025-10-15]
Prostate cancer diagnosis heavily relies on histopathological evaluation, which is subject to variability. While immunohistochemical staining (IHC) assists in distinguishing benign from malignant tissue, it increases workload, costs, and leads to diagnostic delays. Artificial intelligence (AI) presents a promising solution to reduce reliance on IHC by accurately classifying atypical glands and borderline morphologies in hematoxylin and eosin (H&E) stained tissue sections. In this study, we evaluated an AI model's ability to minimize IHC use without compromising diagnostic accuracy. We retrospectively analyzed prostate core needle biopsies from routine diagnostics at three different pathology sites. These cohorts consisted exclusively of diagnostically challenging cases where pathologists had required IHC to finalize the diagnosis. We show that the AI model achieves high performance, with area under the curve values ranging from 0.951 to 0.993 for detecting cancer in routine H&E-stained slides. When applying sensitivity-prioritized diagnostic thresholds, the model reduces the need for IHC staining by 44.4%, 42.0%, and 20.7% across the three cohorts, without a single false negative prediction. Among slides with a benign ground truth label, IHC use is reduced by up to 80.6%. This AI model shows promise for reducing unnecessary IHC use in difficult prostate biopsy cases while maintaining diagnostic safety. Its integration into clinical workflows could streamline decision-making in prostate pathology and alleviate resource burdens.
PubMed 41094148
DOI 10.1038/s43856-025-01185-y
Crossref 10.1038/s43856-025-01185-y
pmc: PMC12528698
pii: 10.1038/s43856-025-01185-y